ArticleInternational journal of clinical and experimental pathology2026
LncRNA FENDRR is involved in the progression and cisplatin resistance of non-small cell lung cancer via binding to DGCR8.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOvercoming chemoresistance is a major therapeutic challenge to improve patient's outcome, and lncRNAs are involved in the carcinogenesis and progression of NSCLC. Accordingly, this study was aimed to explore the roles and functions of lncRNA FENDRR in the progression and drug resistance of NSCLC.
methodsThe University of California Santa Cruz (UCSC) Xena browser was used to validate the putative profile of lncRNA FENDRR in pan-cancer tissues, whereas Kaplan-Meier analysis was conducted to assess the overall survival rate. The potential mechanism underlying cisplatin (DDP) resistance was then investigated using transfection of siRNA-FENDRR or pcDNA3.1/FENDRR
resultsLncRNA FENDRR was lowly expressed in 28 types of tumor tissues, especially in A549/DDP-resistant cells and the patients with DDP resistance. LncRNA FENDRR downregulation was associated with poor survival for patients with NSCLC. Conversely, FENDRR overexpression was observed to suppress cell viability and clonogenic ability, enhance sensitivity to cisplatin in DDP-resistant NSCLC cells and simultaneously induced their apoptosis. However, FENDRR knockdown led to opposite effects on A549 cells. Furthermore, FENDRR was predominantly located in nucleus, where its overexpression suppressed tumor proliferation in A549/DDP cells by directly targeting DGCR8.
conclusionsTaken together, these findings suggest evidence of FENDRR in the emergence of NSCLC and further reveal a key role of the FENDRR/DGCR8 axis in the progression and drug resistance in this cancer, thereby implicating a FENDRR-targeted therapeutic strategy for combating DDP resistance in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.